Metformin vs Rapamycin
Metformin and Rapamycin are both metabolic compounds evaluated on Vial: Metformin is FDA approved with clinical-trial evidence, and Rapamycin is FDA approved with clinical-trial evidence.
Vial summary · compiled from public records
At a glance
Side by side
| Field | Metformin | Rapamycin |
|---|---|---|
| Category | Metabolic | Metabolic |
| Brand names | — | — |
| FDA / legal status | FDA Approved | FDA Approved |
| Evidence tier | Clinical Trials | Clinical Trials |
| Administration route | — | — |
| Compounding access | FDA-approved product, dispensed by prescription | FDA-approved product, dispensed by prescription |
| Providers on Vial | 0 listed | 0 listed |
| Typical price band | Varies by provider | Varies by provider |
Verified providers offering each
Ranked by Confidence Rating, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.
Metformin0 top providers
No surfaceable providers currently list Metformin on Vial.
See all 0 providers offering metformin →Rapamycin0 top providers
No surfaceable providers currently list Rapamycin on Vial.
See all 0 providers offering rapamycin →About each compound
About Metformin
Metformin is the world's most prescribed diabetes drug and a leading candidate for the first FDA-approved longevity drug via the TAME (Targeting Aging with Metformin) trial. Epidemiological data consistently shows metformin users have lower rates of cancer, cardiovascular disease, and all-cause mortality compared to matched diabetic controls. It is widely used off-label by longevity-focused physicians. Side effects are minimal at low doses.
About Rapamycin
Rapamycin (sirolimus) is an FDA-approved immunosuppressant that is the most robust longevity-extending drug identified in animal models, extending lifespan in mice by 9–14% even when started late in life. It works by inhibiting mTORC1, a central nutrient-sensing pathway. Low-dose, intermittent protocols are being studied and self-administered by longevity researchers for healthspan extension. It carries meaningful immunosuppression risks requiring physician oversight.
Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.
Related compound comparisons
Other comparisons in the same category.